Filing Analysis
Apyx Medical Corp entered into a letter agreement on June 11, 2026, appointing Stavros Vizirgianakis as Executive Chairman of the Board. In connection with this role, Mr. Vizirgianakis was granted 450,000 restricted stock units (RSUs) with a tiered vesting schedule.
🚩 Red Flags
- Related-party transaction: Significant equity grant to the Chairman of the Board.
- Immediate vesting of 150,000 RSUs (one-third of the total grant) upon appointment.
📋 Key Facts
- Appointment of Stavros Vizirgianakis as Executive Chairman effective June 11, 2026.
- Grant of 450,000 restricted stock units (RSUs) under the 2023 Share Incentive Plan.
- Vesting schedule: 150,000 RSUs vested immediately on June 11, 2026; 150,000 RSUs vest ratably over 12 months starting June 11, 2027; 150,000 RSUs vest ratably over 12 months starting June 11, 2028.
- Mr. Vizirgianakis will not be designated as an 'executive officer' per Rule 3b-7 of the Exchange Act.
Apyx Medical Corporation announced the publication of new clinical data in the Aesthetic Surgery Journal Open Forum. The study highlights a promising approach to treating cellulite and skin laxity, two common aesthetic concerns, using the company's technology.
📋 Key Facts
- Filing date: May 21, 2026
- The clinical data was published in the peer-reviewed Aesthetic Surgery Journal Open Forum
- The study focuses on improving cellulite and skin laxity
- The announcement was made via a press release attached as Exhibit 99.1
Apyx Medical Corporation announced the publication of a retrospective investigator-initiated study in a peer-reviewed medical journal. The study evaluated patient-reported outcomes for the company's Renuvion product when used in conjunction with liposuction.
📋 Key Facts
- The study was published in 'Plastic and Reconstructive Surgery - Global Open' on May 14, 2026.
- The research compared outcomes of liposuction alone versus liposuction combined with helium plasma radiofrequency (Renuvion).
- The study is categorized as a retrospective investigator-initiated study, which typically carries less weight than prospective, company-sponsored pivotal trials.
- The filing was made under Item 8.01 (Other Events).
Apyx Medical Corporation announced it has received expanded 510(k) clearance from the U.S. FDA for its AYON Body Contouring System. The expanded clearance specifically allows the system to include power liposuction capabilities.
📋 Key Facts
- On May 11, 2026, the company received expanded 510(k) clearance from the FDA.
- The clearance pertains to the AYON Body Contouring System.
- The expansion adds power liposuction to the system's cleared indications for use.
Apyx Medical Corporation furnished its first quarter 2026 financial results via a press release on May 7, 2026. The filing covers the three-month period ended March 31, 2026.
📋 Key Facts
- Earnings release for Q1 ended March 31, 2026
- Filed under Item 2.02 (Results of Operations and Financial Condition)
- Press release included as Exhibit 99.1
- Matthew Hill, CFO, signed the filing
Apyx Medical Corporation reported its financial results for the fourth quarter and full year ended December 31, 2025, via a press release on March 10, 2026.
📋 Key Facts
- The company reported results for the fourth quarter and fiscal year ended December 31, 2025
- The information was furnished under Item 2.02 Results of Operations and Financial Condition
- The full press release is included as Exhibit 99.1
- The filing was signed by Matthew Hill, Chief Financial Officer